Published ahead of print on August 24, 2006, doi:10.1164/rccm.200509-1405OC
American Journal of Respiratory and Critical Care Medicine Vol 174. pp. 1101-1109, (2006)
© 2006 American Thoracic Society
doi: 10.1164/rccm.200509-1405OC
Sequence, Haplotype, and Association Analysis of ADR 2 in a Multiethnic Asthma Case-Control Study
Gregory A. Hawkins,
Kelan Tantisira,
Deborah A. Meyers,
Elizabeth J. Ampleford,
Wendy C. Moore,
Barbara Klanderman,
Stephen B. Liggett,
Stephen P. Peters,
Scott T. Weiss and
Eugene R. Bleecker
Center for Human Genomics, Wake Forest University School of Medicine, Winston-Salem, North Carolina; Channing Laboratory, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio
Correspondence and requests for reprints should be addressed to Eugene Bleecker, M.D., Section of Pulmonary, Critical Care, Allergy and Immunologic Diseases Center for Human Genomics, Wake Forest University Health Sciences, Winston-Salem, NC 27157. E-mail: ebleeck{at}wfubmc.edu
Rationale: The comprehensive evaluation of gene variation, haplotype structure, and linkage disequilibrium is important in understanding the function of 2-adrenergic receptor gene (ADR 2) on disease susceptibility, pulmonary function, and therapeutic responses in different ethnic groups with asthma.
Objectives: To identify ADR 2 polymorphisms and haplotype structure in white and African American subjects and to test for genotype and haplotype association with asthma phenotypes.
Methods: A 5.3-kb region of ADR 2 was resequenced in 669 individuals from 429 whites and 240 African Americans. A total of 12 polymorphisms, representing an optimal haplotype tagging set, were genotyped in whites (338 patients and 326 control subjects) and African Americans (222 patients and 299 control subjects).
Results: A total of 49 polymorphisms were identified, 21 of which are novel; 31 polymorphisms (frequency > 0.03) were used to identify 24 haplotypes (frequency > 0.01) and assess linkage disequilibrium. Association with ratio (FEV1/FVC)2 for single-nucleotide polymorphism +79 (p < 0.05) was observed in African Americans. Significant haplotype association for (FEV1/FVC)2 was also observed in African Americans.
Conclusions: There are additional genetic variants besides +46 (Gly16Arg) that are important in determining asthma phenotypes. These data suggest that the length of a poly-C repeat (+1269) in the 3' untranslated region of ADR 2 may influence lung function, and may be important in delineating variation in -agonist responses, especially in African Americans.
Key Words: asthma 2-adrenergic receptor -agonist therapy DNA polymorphisms pharmacogenomics
| AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Gene variation and haplotypes relating to the effects of the gene ADR 2 on disease susceptibility and therapeutic responses had been previously studied in only a limited fashion.
What This Study Adds to the Field
There are additional ADR 2 genetic variants besides +46 (Gly16Arg) and +79 (Gln27Glu) that are important in determining asthma phenotypes.
|
This article has been cited by other articles:

|
 |

|
 |
 
A. J. Sehnert, S. E. Daniels, M. Elashoff, J. A. Wingrove, C. R. Burrow, B. Horne, J. B. Muhlestein, M. Donahue, S. B. Liggett, J. L. Anderson, et al.
Lack of Association Between Adrenergic Receptor Genotypes and Survival in Heart Failure Patients Treated With Carvedilol or Metoprolol
J. Am. Coll. Cardiol.,
June 23, 2008;
(2008)
j.jacc.2008.05.022v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Panebra, M. R. Schwarb, S. M. Swift, S. T. Weiss, E. R. Bleecker, G. A. Hawkins, and S. B. Liggett
Variable-length poly-C tract polymorphisms of the {beta}2-adrenergic receptor 3'-UTR alter expression and agonist regulation
Am J Physiol Lung Cell Mol Physiol,
February 1, 2008;
294(2):
L190 - L195.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. E. Moore
Exploration of the {beta}2-adrenergic receptor regulatory regions: the next step in the holy grail of asthma pharmacogenetics research
Am J Physiol Lung Cell Mol Physiol,
February 1, 2008;
294(2):
L187 - L189.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Hizawa, H. Makita, Y. Nasuhara, T. Betsuyaku, Y. Itoh, K. Nagai, M. Hasegawa, and M. Nishimura
{beta}2-Adrenergic Receptor Genetic Polymorphisms and Short-term Bronchodilator Responses in Patients With COPD
Chest,
November 1, 2007;
132(5):
1485 - 1492.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. B. Penn, V. E. Ortega, and E. R. Bleecker
A Roadmap to functional genomics
Physiol Genomics,
June 19, 2007;
30(1):
82 - 88.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Panebra, M. R. Schwarb, C. B. Glinka, and S. B. Liggett
Allele-Specific Binding of Airway Nuclear Extracts to Polymorphic beta2-Adrenergic Receptor 5' Sequence
Am. J. Respir. Cell Mol. Biol.,
June 1, 2007;
36(6):
654 - 660.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. C. Moore and S. P. Peters
Update in Asthma 2006
Am. J. Respir. Crit. Care Med.,
April 1, 2007;
175(7):
649 - 654.
[Full Text]
[PDF]
|
 |
|
Copyright © 2006 American Thoracic Society
|
|
|